CClinicalTrials.gg
Sign In
Enrolling by invitationNCT07280221Updated Sep 30, 2026

WEgovy Real World Assessment of Weight Loss in Korea

An observational study in Obesity, sponsored by Novo Nordisk A/S. Enrolling by invitation at 18 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Novo Nordisk A/S · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
19 Years and older
Sex
All
01

Study summary

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

02

Conditions studied

  • Obesity

Browse trials for

03

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

Inclusion criteria

  1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
  3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
  4. Male or female, aged ≥ 19 years at the time of signing the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
  2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
  3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Once weekly Wegovy

    Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

    Drug: Semaglutide

Interventions

  • DrugSemaglutide

    Semaglutide injection will be self-administered once weekly subcutaneously.

05

What researchers measure

Primary outcomes

  1. Percentage change in body weight

    Percent (%)

    Time frame: From baseline (week 0) to 24 weeks

Secondary outcomes

  1. Absolute change in body weight

    Kilogram (kg)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  2. Percentage change in body weight

    Percent (%)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  3. Achievement in body weight reduction more than or equal to (≥) 5%

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  4. Achievement in body weight reduction ≥ 10%

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  5. Achievement in body weight reduction ≥ 15%

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  6. Achievement in body weight reduction ≥ 20%

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  7. Change in body composition of Lean body mass

    Kg

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  8. Change in body composition of Total fat mass

    Kg

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  9. Change in body composition of Lean body mass

    Percent (%)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  10. Change in body composition of Total fat mass

    Percent (%)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  11. Change in Body mass index (BMI)

    Kilogram per meter square (kg/m\^2)

    Time frame: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks

  12. Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  13. Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  14. Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)

    Count of patients

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  15. Change in waist circumference

    Centimetre (cm)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  16. Change in cardiometabolic parameters - Systolic blood pressure (SBP)

    Millimetres of mercury (mmHg)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  17. Change in cardiometabolic parameters - Diastolic blood pressure (DBP)

    mmHg

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  18. Change in cardiometabolic parameters - Fasting plasma glucose (FPG)

    Milligram per deciliter (mg/dL)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  19. Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)

    Percent (%)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  20. Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)

    mg/dL

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  21. Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)

    mg/dL

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  22. Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)

    mg/dL

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  23. Change in cardiometabolic parameters - Lipids: triglycerides (TG)

    mg/dL

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  24. Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)

    mg/dL

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

  25. Change in status of type two diabetes mellitus (T2DM)

    Count of patients

    Time frame: Baseline (week 0) to 52 weeks [or end of the study (EOS)]

  26. Change in status of Hypertension

    Count of patients

    Time frame: Baseline (week 0) to 52 weeks (or EOS)

  27. Change in status of Dyslipidemia

    Count of patients

    Time frame: Baseline (week 0) to 52 weeks (or EOS)

  28. Number of treatment-emergent adverse events (TEAEs)

    Count of events

    Time frame: From baseline (week 0) to 52 weeks (or EOS)

  29. Number of serious TEAEs

    Count of events

    Time frame: From baseline (week 0) to 52 weeks (or EOS)

06

Study locations

18 sites
  • National Health Insurance Corporation Ilsan Hospital
    Goyang-si, Gyeonggi-do 10444, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, South Korea
  • The Catholic University of Korea. Uijeongbu St. Mary's Hospital
    Uijeongbu-si, Gyeonggi-do 11765, South Korea
  • Pusan National University Yangsan Hospital
    Yangsan, Gyeongsangnam-do 50612, South Korea
  • Inje University Haeundae Paik Hospital
    Busan, 48108, South Korea
  • Dong-A University Hospital
    Busan, 49201, South Korea
  • Keimyung University Dongsan Hospital
    Daegu, 42601, South Korea
  • Daejeon Endo Internal Medicine Clinic
    Daejeon, 35220, South Korea
  • Konyang University Hospital
    Daejeon, 35365, South Korea
  • Chung-Ang University Gwangmyeong Hospital
    Gwangmyeong-si, Gyeonggi-do, 14353, South Korea
  • CHA Bundang Medical Center
    Seongnam-si, Gyeonggi-do, 13496, South Korea
  • Seoul Happiness Clinic of internal medicine
    Seongnam-si, Gyeonggi-do, 13612, South Korea
  • Chung-Ang University Hospital
    Seoul, 06973, South Korea
  • Ewha Womans University Seoul Hospital
    Seoul, 07804, South Korea
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
  • Uijeongbu Eulji university Hospital
    Uijeongbu-si, Gyeonggi-do, 11759, South Korea
  • Yongin Severance Hospital
    Yongin-si, 16995, South Korea
07

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07280221
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Nov 10, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity→

Other studies from this sponsor

Novo Nordisk A/S

Start the discussion